| The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States M Zhdanava, D Pilon, I Ghelerter, W Chow, K Joshi, P Lefebvre, ... The Journal of clinical psychiatry 82 (2), 29169, 2021 | 355 | 2021 |
| Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients F Laliberte, M Cloutier, WW Nelson, CI Coleman, D Pilon, WH Olson, ... Current medical research and opinion 30 (7), 1317-1325, 2014 | 249 | 2014 |
| Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US commercial claims database TB Amos, N Tandon, P Lefebvre, D Pilon, RL Kamstra, I Pivneva, ... The Journal of clinical psychiatry 79 (2), 5360, 2018 | 151 | 2018 |
| Treatment patterns, health care resource utilization, and spending in Medicaid beneficiaries initiating second-generation long-acting injectable agents versus oral atypical … D Pilon, N Tandon, MH Lafeuille, R Kamstra, B Emond, P Lefebvre, ... Clinical Therapeutics 39 (10), 1972-1985. e2, 2017 | 99 | 2017 |
| Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy JF Dasta, D Pilon, SH Mody, J Lopatto, F Laliberté, G Germain, ... Thrombosis research 135 (2), 303-310, 2015 | 74 | 2015 |
| Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy JA Simon, F Laliberté, MS Duh, D Pilon, KH Kahler, J Nyirady, PJ Davis, ... Menopause 23 (6), 600-610, 2016 | 56 | 2016 |
| Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy D Pilon, AS Behl, LA Ellis, MN Robitaille, P Lefebvre, NA Dawson American health & drug benefits 10 (3), 143, 2017 | 51 | 2017 |
| Treatment patterns in Medicaid patients with schizophrenia initiated on a first-or second-generation long-acting injectable versus oral antipsychotic D Pilon, K Joshi, N Tandon, MH Lafeuille, RL Kamstra, B Emond, ... Patient preference and adherence, 619-629, 2017 | 51 | 2017 |
| Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults … D Pilon, E Muser, P Lefebvre, R Kamstra, B Emond, K Joshi BMC psychiatry 17, 1-18, 2017 | 50 | 2017 |
| Medication adherence, treatment patterns, and dose reduction in patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate or enzalutamide AS Behl, LA Ellis, D Pilon, Y Xiao, P Lefebvre American health & drug benefits 10 (6), 296, 2017 | 44 | 2017 |
| Burden of treatment-resistant depression in Medicare: a retrospective claims database analysis D Pilon, K Joshi, JJ Sheehan, ML Zichlin, P Zuckerman, P Lefebvre, ... PLoS One 14 (10), e0223255, 2019 | 43 | 2019 |
| The economic burden of psoriasis with high comorbidity among privately insured patients in the United States D Pilon, A Teeple, M Zhdanava, M Ladouceur, H Ching Cheung, E Muser, ... Journal of Medical Economics 22 (2), 196-203, 2019 | 36 | 2019 |
| Burden of Crohn’s disease in the United States: long-term healthcare and work-loss related costs AM Manceur, Z Ding, E Muser, C Obando, J Voelker, D Pilon, F Kinkead, ... Journal of medical economics 23 (10), 1092-1101, 2020 | 34 | 2020 |
| Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer D Pilon, M Queener, P Lefebvre, LA Ellis Journal of medical economics 19 (8), 777-784, 2016 | 34 | 2016 |
| Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? F Laliberte, D Pilon, MK Raut, WW Nelson, WH Olson, G Germain, ... Current medical research and opinion 30 (4), 645-653, 2014 | 34 | 2014 |
| Treatment sequences and pharmacy costs of 2 new therapies for metastatic castration-resistant prostate cancer LA Ellis, MH Lafeuille, L Gozalo, D Pilon, P Lefebvre, S McKenzie American health & drug benefits 8 (4), 185, 2015 | 29 | 2015 |
| Medicaid spending burden among beneficiaries with treatment-resistant depression D Pilon, JJ Sheehan, H Szukis, D Singer, P Jacques, D Lejeune, ... Journal of comparative effectiveness research 8 (6), 381-392, 2019 | 27 | 2019 |
| Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population D Pilon, Z Ding, E Muser, C Obando, J Voelker, AM Manceur, F Kinkead, ... Current Medical Research and Opinion 36 (8), 1285-1294, 2020 | 23 | 2020 |
| Matching-adjusted indirect comparison of health-related quality of life and adverse events of apalutamide versus enzalutamide in non-metastatic castration-resistant prostate cancer S Chowdhury, S Oudard, H Uemura, S Joniau, D Pilon, P Lefebvre, ... Advances in therapy 37, 512-526, 2020 | 23 | 2020 |
| Matching-adjusted indirect comparison of the efficacy of apalutamide and enzalutamide with ADT in the treatment of non-metastatic castration-resistant prostate cancer S Chowdhury, S Oudard, H Uemura, S Joniau, D Pilon, M Ladouceur, ... Advances in therapy 37, 501-511, 2020 | 21 | 2020 |